Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute of Rheumatology, NDORMS have identified a new target for treatment of particular inflammatory conditions, with the findings published this week in PNAS.

Blocking the protein interferon regulatory factor 5 (IRF5) would significantly reduce inflammation in certain chronic conditions, providing a more specific and effective treatment for patients, as well as fewer side effects from long-term use of current options.

Macrophages and neutrophils, two types of white blood cells, are the most abundant inflammatory cells in diseases driven by inflammation, like rheumatoid arthritis and acute lung injury. Each cell type can play opposing roles, with some macrophages increasing inflammation whilst other macrophages are helping to decrease it. Reducing the presence of these cells in inflamed areas, or switching their function to a ‘repair’ one, typically leads to profound therapeutic benefit.

IRF5 is very important in defining which role macrophages will play, as well as in neutrophil recruitment to affected areas, namely on acute lung injury, making it a great target for new therapies.

Kennedy researcher Miriam Weiss said: "These data highlight IRF5 as a very interesting drug target to treat inflammatory diseases such as rheumatoid arthritis. The next step will be to find ways to block this pathway, so we can move closer to an effective therapy."

You can read the full article here.

Image: neutrophils detected within the synovial capsule of inflamed knees. Left: control group; right: blocking IRF5.

Similar stories

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.

New research could improve quality of life for Psoriatic Arthritis patients

Professors Laura Coates and Dani Prieto-Alhambra will take major roles in a new European Commission project to develop innovative personalised treatment options for people affected by psoriatic arthritis.